Selective estrogen receptor modulators in clinical practice: a safety overview
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Selective estrogen receptor modulators in clinical practice: a safety overview
Authors
Keywords
-
Journal
Expert Opinion On Drug Safety
Volume 14, Issue 6, Pages 921-934
Publisher
Informa Healthcare
Online
2015-05-02
DOI
10.1517/14740338.2015.1014799
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Toremifene for Breast Cancer: A Review of 20 Years of Data
- (2013) Charles L. Vogel et al. Clinical Breast Cancer
- Assessment of the safety of long-term bazedoxifene treatment on the reproductive tract in postmenopausal women with osteoporosis: Results of a 7-year, randomized, placebo-controlled, phase 3 study
- (2013) Santiago Palacios et al. MATURITAS
- Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy
- (2013) David J. Portman et al. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY
- Effects of toremifene versus tamoxifen on breast cancer patients: a meta-analysis
- (2012) Feng Chi et al. Breast Cancer
- The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy
- (2011) Suzanne E. Wardell et al. BIOCHEMICAL PHARMACOLOGY
- The Selective Estrogen Receptor Modulator Bazedoxifene Inhibits Hormone-Independent Breast Cancer Cell Growth and Down-Regulates Estrogen Receptor and Cyclin D1
- (2011) J. S. Lewis-Wambi et al. MOLECULAR PHARMACOLOGY
- Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study
- (2011) S. L. Silverman et al. OSTEOPOROSIS INTERNATIONAL
- Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled phase 3 study of postmenopausal women with osteoporosis
- (2010) Claus Christiansen et al. BMC MUSCULOSKELETAL DISORDERS
- Lasofoxifene and Cardiovascular Events in Postmenopausal Women With Osteoporosis
- (2010) Kristine Ensrud et al. CIRCULATION
- Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer
- (2010) Angelo Di Leo et al. JOURNAL OF CLINICAL ONCOLOGY
- Breast Cancer Incidence in the Randomized PEARL Trial of Lasofoxifene in Postmenopausal Osteoporotic Women
- (2010) A. Z. LaCroix et al. JNCI-Journal of the National Cancer Institute
- Postmenopausal Evaluation and Risk Reduction With Lasofoxifene (PEARL) trial
- (2010) Steven R. Goldstein et al. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY
- Lasofoxifene in Postmenopausal Women with Osteoporosis
- (2010) Steven R. Cummings et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial
- (2010) T. J. de Villiers et al. OSTEOPOROSIS INTERNATIONAL
- Bazedoxifene, a selective estrogen receptor modulator
- (2009) David F. Archer et al. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY
- Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis
- (2009) JoAnn V. Pinkerton et al. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY
- Cohort Studies: Prospective versus Retrospective
- (2009) Anne M. Euser et al. NEPHRON CLINICAL PRACTICE
- Prospective assessment of the endometrium in postmenopausal breast cancer patients treated with fulvestrant
- (2008) Leilani Morales et al. BREAST CANCER RESEARCH AND TREATMENT
- Efficacy of Bazedoxifene in Reducing New Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis: Results From a 3-Year, Randomized, Placebo-, and Active-Controlled Clinical Trial*
- (2008) Stuart L Silverman et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro
- (2007) H Michael et al. BRITISH JOURNAL OF PHARMACOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started